Differences in HPV Immunization Levels Among Young Adults in Various Regions of the United States
- 462 Downloads
HPV vaccine uptake in young adult women in the Southern US has been previously found to be the lowest in the country. In addition, geographic variation with regard to HPV vaccination among young adult men has not been investigated yet. The objective of this study was to use the most recent data to determine if inequality still exists. We used Behavioral Risk Factor Surveillance System 2012 data from 8 states (no data available from Midwest) to examine the geographic variations in weighted proportion of adults who initiated (≥1 dose) and completed (3 doses) the HPV vaccine among 3727 young adults (2014 women and 1713 men) 18–26 years old based on self-reported HPV vaccination and socio-demographic characteristics. The weighted vaccine initiation and completion rates among men were: 6.3 and 1.7 % overall, 8.5 and 2.2 % in the Northeast, 6.7 and 1.6 % in the West, and 4.9 and 1.4 % in the South (p = 0.184 and 0.774). The rates among women were: 40.4 % and 27.4, 58.7 and 45.6 %, 39.0 and 24.8 %, and 30.4 and 17.7 % in the respective regions (p < 0.001 for both). Adjusted multivariable logistic regression showed that women living in the South and West were less likely to initiate and complete the 3-dose HPV vaccine series when compared to those in the Northeast. Despite an increase in HPV vaccine uptake among young adult women in all regions, geographic disparity still exists. Moreover, young adult men had very low HPV vaccine initiation and completion rates throughout the US.
KeywordsHuman papillomavirus (HPV) HPV vaccine Vaccine initiation Vaccine completion Young adults Geographic variation
Conflict of interest
- 1.Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 56, 1–24.Google Scholar
- 2.Centers for Disease Control and Prevention. (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendation from the Advisory Committee on Immunization Practices (ACIP). MMWR, 59, 626–629.Google Scholar
- 4.Paavonen, J., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S. N., et al. (2009). Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet, 374, 301–314.CrossRefPubMedGoogle Scholar
- 11.Centers for Disease Control and Prevention (CDC). (2012). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention (also Available at http://www.cdc.gov/brfss/annual_data/2012/response_rates_12.htm).
- 12.Centers for Disease Control and Prevention (CDC). (2012). Behavioral risk factor surveillance system survey questionnaire. Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention.Google Scholar
- 18.Renwick, T. (2011). Geographic Adjustments of supplemental poverty measure thresholds: Using the American community survey five-year data on housing costs. US Census Bureau. SEHSD Working Paper Number 2011–21 Available at https://www.census.gov/hhes/povmeas/methodology/supplemental/research/RenwickGeographicAdjustmentsJuly2011WEA.pdf.